Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study
Authors:
Open Access
- 3 February 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (5) , e32866
Abstract
Kaposi sarcoma is an angioproliferative disease associated with human herpes virus 8 infection. Classic Kaposi sarcoma (CKS) usually develops in older age. Although CKS often does not require systemic therapy, systemic therapy can be administered in progressively symptomatic patients. In this real-life study, we purposed to determine effectiveness and safety of weekly paclitaxel therapy in the first-line treatment of CKS. In this cross-sectional retrospective study, we analyzed the clinical data of 44 patients with CKS who received first-line paclitaxel therapy between January 2000 and December 2020. Paclitaxel was administered by intravenous infusion 80 to 100 mg/weekly. The median age of the patients was 67 years (range, 39–86 years), and majority male (77.2%). All patients had cutaneous involvement in extremities. The median follow-up time from paclitaxel treatment was 39.1 (range, 3.7–173.5) months. The median progression free survival from start of therapy was 35.1 months (range, 2–144 months). Complete response, partial response and stable disease were observed in 7 (15.9%), 28 (63.7%) and 6 (13.6) patients, respectively. Objective control rate was 79.6%, and the median response time after the last dose of paclitaxel was 18.2 months. A total of 4 patients (9.1%) had grade 3 to 4 neutropenia, but it was not complicated by febrile neutropenia. Three patients (6.8%) experienced grade 3 to 4 peripheral neuropathy. No patient had grade 3 to 4 allergic reaction. There was no drug-related death. According to our results, paclitaxel is an effective therapy option with an acceptable safety profile for patients with advanced CKS.Keywords
This publication has 22 references indexed in Scilit:
- Treatments for classic Kaposi sarcoma: A systematic review of the literatureJournal of the American Academy of Dermatology, 2013
- Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcomaCancer, 2010
- Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 casesBritish Journal of Dermatology, 2008
- Treatment with taxanes of refractory or life‐threatening Kaposi sarcoma not associated with human immunodeficiency virus infectionCancer, 2006
- Kaposi's sarcoma: An updateJournal of Surgical Oncology, 2004
- Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcomaCancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- Classic and Iatrogenic Kaposiʼs SarcomaThe American Journal of Dermatopathology, 1993
- Idiopathisches multiples Pigmentsarkom der HautArchives of Dermatological Research, 1872